IT - EN
Investors

InvestorsNews & AnnouncementsBusiness & financial news

2020, June 17 RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE
2020, June 2 Recordati Rare Diseases announces first European launch of Isturisa® (osilodrostat)
2020, May 27 RECORDATI RARE DISEASES INC. ANNOUNCES AVALABILITY OF ISTURISA® (OSILODROSTAT) IN THE UNITED STATES
2020, May 7 - 12:35 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
2020, April 29 - 12:11 RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
2020, April 8 Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome
2020, March 26 RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
2020, March 18 RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19
2020, March 18 - 14:11 BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%).
2020, March 12 - 19:59 RECORDATI: LAUNCH OF A NEW SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS
2020, March 9 - 08:32 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN THE U.S.
2020, February 17 - 19:29 RECORDATI: LAUNCH OF A SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS
2020, February 14 - 14:04 RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%.
2020, February 4 RECORDATI: CHANGE IN 2020 CORPORATE EVENTS’ CALENDAR
2020, January 15 - 12:01 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED
= price sensitive (as from 2015)